Alzheimer's Disease Clinical Trial
Official title:
A Prospective, Single Site, Single Arm, Non-randomized, Interventional Study to Evaluate the Safety and Effectiveness of Omental Transposition Surgery for Patients With Alzheimer's Disease.
This study is a prospective, single arm, non-randomized, interventional study to evaluate
the safety and effectiveness of Omental transposition (OT) in subjects with early stage AD.
Within-subjects (repeated-measures) design will be utilized to compare follow-up outcomes to
baseline.
The following assessments will be performed at baseline, then at 1, 3, 6, 12, and 24 months
following surgery:
- Montreal Cognitive Assessment (MoCA)
- Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog)
- General Practitioner Assessment of Cognition (GPCOG)
- Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Subjects who
have early stage AD confirmed by a neuropsychological test (MoCA) and who are healthy
enough to undergo surgery.
The experimental procedure to be performed is omental transposition (OT) surgery. It will be
performed as a laparoscopic or open procedure for omental lengthening and an open procedure
for brain access, with a general surgeon performing the omental lengthening/tunneling and a
neurosurgeon performing brain access/brain biopsy/omental placement on brain.
Up to twenty-five (25) subjects, with the first 5 subjects being part of a learning curve
group and the next 20 subjects being part of the experimental group.
The duration of each subject's participation will be approximately 25 months from screening
through the 24 month follow-up visit.
Status | Not yet recruiting |
Enrollment | 25 |
Est. completion date | May 2019 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Male or female subjects between 60 to 85 years of age 2. Montreal Cognitive Assessment (MoCA) score of 11 to 18 (mild AD) 3. Healthy enough to undergo the surgical procedure based on surgical risk factor definitions (ASA = 3, using the ASA classification) 4. Must be able to read and understand English in order to complete all AD assessments 5. All medical illnesses other than dementia must be well controlled 6. Must have legally authorized caregiver if incapable of making their own decisions who is willing and able to perform the following: 1. provide informed consent if the subject is unable to do so; 2. monitor the subject; 3. answer informant based questionnaires; 4. provide transportation and accompany the subject to all visits 7. Subject or caregiver is willing and able to provide written informed consent and assent (if applicable) 8. Subject and/or caregiver are willing to comply with the study procedures and complete the entire study as specified in the protocol Exclusion Criteria: 1. Life expectancy < 2 years 2. Subject who had or has cancer and is undergoing cancer therapy 3. Previous course of abdominal, cranial or neck radiotherapy or chemotherapy 4. Patients with neck calcifications may be excluded 5. Subject with uncontrolled heart disease, renal disease, or liver disease 6. Subject with diabetes mellitus whose glycoslated Hb (A1C) > 7 7. Complete blood count (CBC) with white blood cell <4,000 or platelets >125,000 8. Subject with uncontrollable hypertension (HTN) 9. Subject with previous abdominal surgery or disorder that could negatively influence the outcome of the OT surgery 10. Subject who has had a craniotomy in the past 11. Recent major surgery within the past 6 months 12. Use of cholinesterase inhibitors within the last 30 days and inability to not take cholinesterase inhibitors throughout the length of the study (about 25 mos) 13. Subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence 14. Use of anticoagulants other then anti-platelet medications 15. Subject has significant central nervous system (CNS) disorder other than Alzheimer's disease 16. Subject has clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness =15 minutes 17. Major depressive disorder, schizophrenia, other psychotic disorders, or bipolar disorder 18. Subject has epilepsy 19. Patients with severe extra pyramidal signs 20. Patients with plastic surgery of the neck or face 21. Subject resides in hospital or moderate to high dependency continuous care facility 22. Non-English speaking subjects and/or caregivers 23. Subject has any condition that, in the opinion of the Investigator would preclude the use of the study procedure, may interfere with the evaluation of the procedure-related outcomes, or preclude the subject from completing the follow-up requirements |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bariatric Medicine Institute, Salt Lake City, UT |
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. — View Citation
Goldsmith HS, Sax DS. Omental transposition for cerebral infarction: a 13-year follow-up study. Surg Neurol. 1999 Mar;51(3):342-5; discussion 345-6. — View Citation
Goldsmith HS. Omental transposition for Alzheimer 's disease. Neurol Res. 1996 Apr;18(2):103-8. — View Citation
Goldsmith HS. Omental transposition in treatment of Alzheimer disease. J Am Coll Surg. 2007 Dec;205(6):800-4. Epub 2007 Sep 18. Review. — View Citation
Goldsmith HS. Treatment of Alzheimer's disease by transposition of the omentum. Ann N Y Acad Sci. 2002 Nov;977:454-67. — View Citation
Shankle WR, Hara J, Bjornsen L, Gade GF, Leport PC, Ali MB, Kim J, Raimo M, Reyes L, Amen D, Rudy L, O'Heany T. Omentum transposition surgery for patients with Alzheimer's disease: a case series. Neurol Res. 2008 Apr;30(3):313-25. Epub 2007 Aug 31. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit. | surgical complications will be assessed from the anesthesia start time through hospital discharge.Total incidence (%) of complications will be calculated and reported,using Clavien-Dindo Classification of Surgical Complications. | Participants will be monitored for postoperative complications for the duration of their hospital stay, an expected average of 2 days. | Yes |
Secondary | Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months. | Percentage of score change, compared to baseline | 12 months | No |
Secondary | Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months | Percentage of score change, compared to baseline | 12 months | No |
Secondary | Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 12 months | Percentage of score change, compared to baseline | 12 months | No |
Secondary | Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 12 months | Percentage of score change, compared to baseline | 12 months | No |
Secondary | Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 24 months | Percentage of score change, compared to baseline | 24 months | No |
Secondary | Change in Montreal Cognitive Assessment (MoCA) score from baseline at 24 months | Percentage of score change, compared to baseline | 24 months | No |
Secondary | Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 24 months | Percentage of score change, compared to baseline | 24 months | No |
Secondary | Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 24 months | Percentage of score change, compared to baseline | 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02089555 -
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
|
N/A |